peptide centric car peptides - peptide-certification-courses CAR Peptide-Centric CARs: A New Frontier in Targeting Intracellular Oncoproteins

peptide-central-scottsdale The landscape of cancer therapy is continuously evolving, with groundbreaking advancements aiming to tackle previously untreatable malignancies. Among these innovations, peptide-centric CARs (PC-CARs) represent a significant leap forward, particularly in their ability to target intracellular oncoproteins.CAR keys to unlock the intracellular immunopeptidome Unlike traditional Chimeric Antigen Receptor (CAR)-T cells that are limited to surface antigens, peptide-centric CARs offer a novel approach to engage cancer drivers within tumor cellsNew Class of "Peptide-Centric" CAR-T Cells Eradicates .... This article delves into the science behind these peptide-centric CARs, their mechanism of action, and their promising applications in treating challenging cancers like neuroblastoma以肽为中心的CAR实现细胞内肿瘤蛋白的交叉HLA靶向 - 新闻.

Understanding Peptide-Centric CARs

Peptide-centric CARs are a specialized type of CAR T-cell therapy engineered to recognize specific peptides presented on the cell surface by Human Leukocyte Antigen (HLA) molecules. These peptides are fragments of intracellular proteins, including oncoproteins, that have been processed and presented to the immune system. The development of peptide-centric CARs is a direct response to the limitations of conventional CAR T-cell therapies, which struggle to target antigens that reside inside the cell作者：M Yarmarkovich·2023·被引用次数：64—We developedpeptide-centricchimeric antigen receptors (PC-CARs) through a counter panning strategy using predicted potentially cross-reactive peptides..

The core innovation of peptide-centric CARs lies in their ability to "see" these intracellular targets by recognizing their fragmented forms displayed on the cell surfacepeptide-centric chimeric antigen receptors to cancer self .... This is achieved through the design of CARs that specifically bind to these peptide-HLA complexesThe study describes PC-CARstargeting the neuroblastoma oncoprotein PHOX2B presented on HLA. TheseCARskill tumor cells across multiple HLA allotypes.. Researchers have employed strategies like counter panning with predicted potentially cross-reactive peptides to develop CARs with high specificity for these target epitopesThe study describes PC-CARstargeting the neuroblastoma oncoprotein PHOX2B presented on HLA. TheseCARskill tumor cells across multiple HLA allotypes..

Mechanism of Action: Breaking HLA Restriction

A key challenge in developing effective immunotherapies is HLA restriction, as different individuals express different HLA alleles. However, research has shown that peptide-centric CARs can overcome this limitation. By targeting specific peptides presented by various HLA allotypes, these CARs can potentially treat a broader patient population. For instance, studies have demonstrated the ability of peptide-centric CARs to target peptides across multiple HLA types, significantly expanding the pool of immunotherapeutic targets.

The mechanism involves the CAR T-cell recognizing a peptide fragment of an oncoprotein that is bound to an HLA molecule on the surface of a cancer cellNew Class of "Peptide-Centric" CAR-T Cells Eradicates .... Upon recognition, the CAR T-cell becomes activated and initiates a cytotoxic response, leading to the elimination of the cancer cellA roadmap for driving CAR T cells toward the oncogenic .... This approach allows for the targeting of oncoproteins that are typically inaccessible to conventional CAR T-cells, such as those encoded by mutated KRAS or the neuroblastoma oncoprotein PHOX2B.

Promising Applications: Neuroblastoma and Beyond

One of the most extensively studied applications of peptide-centric CARs is in the treatment of neuroblastoma, a highly aggressive pediatric cancer.Targeting of intracellular oncoproteins with peptide-centric ... Neuroblastoma is often driven by oncogenic mutations, and peptide-centric CARs offer a way to target these drivers.2023年3月17日—CAR T-cells in Solid Tumors. This month ALSF is showcasing the work of Dr. Mark Yarmarkovich onPeptide-Centric CART cells ... Studies have shown that peptide-centric CARs targeting the PHOX2B oncoprotein can completely and selectively eliminate neuroblastoma tumors in mice. Furthermore, PHOX2B peptide-centric CAR T cells are being investigated in clinical trials for relapsed neuroblastoma, demonstrating the translational potential of this technology.

Beyond neuroblastoma, peptide-centric CARs hold promise for treating other cancers characterized by intracellular oncoproteins.CAR keys to unlock the intracellular immunopeptidome This includes targeting NF1 mutation glioma oncoproteins and other tumor drivers that were previously considered "undruggable" by traditional CAR T-cell approaches作者：Y Sun·2023·被引用次数：17—T cells engineered withpeptide-centricchimeric antigen receptors (PC-CARs) can recognize normally inaccessible tumor antigens once they have been degraded .... The ability to target the oncogenic immunopeptidome of various cancers opens up new avenues for therapeutic interventionNews in Cancer Cell and Gene Therapy.

Future Directions and Research

The development of peptide-centric CARs is an active area of research. Scientists are continuously working to refine the design of these CARs, improve their specificity, and expand their applicability to a wider range of cancers. Computational modeling and advanced screening techniques are playing a crucial role in identifying novel peptide targets and engineering CARs with enhanced efficacy.

The research by Dr...CART Cells. Official Title. Phase 1 Trial of PHOX2BPeptide-CentricChimeric Antigen Receptor Autologous T Cells (PHOX2B PC-CART) for Relapsed Neuroblastoma.. Mark Yarmarkovich and colleagues has been particularly instrumental in establishing the proof of principle for peptide-centric CARs作者：M Yarmarkovich·2021·被引用次数：114—We developedpeptide-centricchimeric antigen receptors (CARs) using a counter-panning strategy with predicted potentially cross-reactive peptides.. Their work on targeting intracellular oncoproteins with peptide-centric CARs has paved the way for further exploration and clinical translation.Targeting NF1 Mutation Glioma Oncoproteins with Peptide ... As our understanding of cancer biology and immunology grows, peptide-centric CARs are poised to become a powerful tool in the fight against cancer, offering hope for patients with limited treatment options.Targeting of intracellular oncoproteins with peptide-centric ... The ongoing research into these centric CARs and their specific peptides continues to push the boundaries of what is possible in cancer immunotherapy.